

Valentina Guarneri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3533071/valentina-guarneri-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154
papers

5,093
citations

33
h-index

69
g-index

170
ext. papers

6,278
ext. citations

5.2
avg, IF

5.52
L-index

#	Paper	IF	Citations
154	Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications.. <i>Cancer Treatment Reviews</i> , 2022 , 102, 102323	14.4	3
153	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. <i>EBioMedicine</i> , 2022 , 75, 103801	8.8	3
152	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series.. <i>Pathology Research and Practice</i> , 2022 , 233, 153872	3.4	
151	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.. <i>European Journal of Cancer</i> , 2022 , 167, 81-91	7.5	0
150	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022 , 7, 100459	6.9	1
149	CTNI-33. METRONOMIC TEMOZOLOMIDE THERAPY IN HEAVILY PRETREATED PATIENTS WITH RECURRENT GLIOBLASTOMA: A LARGE MONO-INSTITUTIONAL RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2021 , 23, vi66-vi67	1	
148	Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study. <i>Breast Cancer Research and Treatment</i> , 2021 , 191, 355	4.4	1
147	Locoregional and Locally Advanced Breast Cancer. <i>UNIPA Springer Series</i> , 2021 , 429-466	0.1	
146	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2021 ,	12.9	6
145	Evolution of HER2-low expression from primary to recurrent breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 137	7.8	4
144	Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. <i>Frontiers in Oncology</i> , 2021 , 11, 705927	5.3	2
143	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 625636	5.3	2
142	Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2021 , 14, 160-164	1	
141	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021 , 27, 3443-3455	12.9	2
140	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. <i>European Journal of Cancer</i> , 2021 , 147, 120-127	7.5	8
139	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
138	Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network during the first and second pandemic waves.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6511-6511	2.2	1

137	Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2021-2021	2.2	1
136	How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center. <i>Frontiers in Oncology</i> , 2021 , 11, 669786	5.3	4
135	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in -Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021 , 8, 570921	4.9	0
134	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103378	7	2
133	Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021 , 98, 102222	14.4	5
132	Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021 , 17, 2513-2527	3.6	0
131	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 829-841	15.4	7
130	Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. <i>Cells</i> , 2021 , 10,	7.9	26
129	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 12	7.8	2
128	Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review. <i>Cancer Management and Research</i> , 2021 , 13, 6537-6566	3.6	3
127	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021 , 153, 133-141	7.5	4
126	Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis. <i>JCO Oncology Practice</i> , 2021 , 17, e1085-e1093	2.3	1
125	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2021 , 7, 101	7.8	5
124	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021 , 154, 21-29	7.5	1
123	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , 2021 ,	5.7	3
122	Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification. <i>Cytokine</i> , 2021 , 146, 155622	4	0
121	Cancer and COVID-19: what do we really know?. <i>Lancet, The</i> , 2020 , 395, 1884-1885	4.0	29
120	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. <i>BMC Cancer</i> , 2020 , 20, 232	4.8	1

119	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102064	14.4	20
118	Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. <i>European Journal of Cancer</i> , 2020 , 136, 7-15	7.5	13
117	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101965	14.4	39
116	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020 , 50, 56-63	3.6	3
115	Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS598-TPS598	2.2	5
114	Olaparib for advanced breast cancer. <i>Future Oncology</i> , 2020 , 16, 717-732	3.6	6
113	An overview of immune checkpoint inhibitors in breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020 , 1,	2.5	2
112	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , 2020 , 87, 102031	14.4	37
111	Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy. <i>JCO Oncology Practice</i> , 2020 , 16, e211-e220	2.3	4
110	Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study. <i>Breast Journal</i> , 2020 , 26, 1296-1301	1.2	8
109	Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 564915	5.3	4
108	Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases. <i>ESMO Open</i> , 2020 , 5, e000843	6	5
107	Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. <i>Oncologist</i> , 2020 , 25, e1355-e1362	5.7	4
106	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1810-1821	4.4	4
105	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020 , 12,	6.6	7
104	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology, The</i> , 2020 , 21, 1455-1464	21.7	20
103	The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	9
102	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020 , 38, 3987-3998	2.2	152

101	Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2 Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020 , 26, 5843-5851	12.9	17
100	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
99	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. <i>Oncologist</i> , 2019 , 24, e1055-e1069	5.7	23
98	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. <i>Journal of Ovarian Research</i> , 2019 , 12, 9	5.5	45
97	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 140, 67-72	7	40
96	Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. <i>Frontiers in Oncology</i> , 2019 , 9, 452	5.3	24
95	Escalation and de-escalation in HER2 positive early breast cancer. <i>Current Opinion in Oncology</i> , 2019 , 31, 35-42	4.2	7
94	Neoplastic Pericardial Effusion: A Monocentric Retrospective Study. <i>Journal of Palliative Medicine</i> , 2019 , 22, 691-695	2.2	6
93	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 2019 , 7, 90		40
92	Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center. <i>Journal of Women's Health</i> , 2019 , 28, 544-550	3	3
91	BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. <i>Breast</i> , 2019 , 47, 77-84	3.6	9
90	Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019 , 9,	3.8	3
89	Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. <i>Cell Stress</i> , 2019 , 3, 284-294	5.5	25
88	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , 2019 , 17, 207	11.4	1
87	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019 , 24, 1424-1431	5.7	11
86	HER2-Positive Early Breast Cancer 2019 , 371-382		
85	Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. <i>Journal of Neuro-Oncology</i> , 2018 , 138, 369-382	4.8	15
84	Olaparib for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 519-530	3.5	25

83	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018 , 37, 36-41	3.6	19
82	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 507-507	2.2	4
81	First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018 , 23, 297-305	5.7	7
80	Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. <i>Oncologist</i> , 2018 , 23, 1289-1299	5.7	16
79	Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary. <i>Frontiers in Oncology</i> , 2018 , 8, 581	5.3	4
78	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018 , 18, 932	4.8	2
77	Immune characterization of breast cancer metastases: prognostic implications. <i>Breast Cancer Research</i> , 2018 , 20, 62	8.3	32
76	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 128, 19-29	7	7
75	Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. <i>Nuclear Medicine Communications</i> , 2017 , 38, 537-545	1.6	7
74	Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017 , 35, 21-26	3.6	12
73	SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. <i>Medical Oncology</i> , 2017 , 34, 75	3.7	17
72	CMET-29. HORMONE RECEPTORS STATUS: A STRONG DETERMINANT OF THE KINETICS OF BRAIN METASTASES OCCURRENCE COMPARED WITH HER2 STATUS IN BREAST CANCER. <i>Neuro-Oncology</i> , 2017 , 19, vi45-vi45	1	78
71	Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. <i>Journal of Neuro-Oncology</i> , 2017 , 131, 369-376	4.8	6
70	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017 , 8, 32626-32638 ¹⁴	3.3	14
69	GD2 expression in breast cancer. <i>Oncotarget</i> , 2017 , 8, 31592-31600	3.3	25
68	Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017 , 37, 3723-3728	2.3	3
67	The impact of adjuvant endocrine therapy in early breast cancer on quality-of-life: an overview of prospective trials. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016 , 1, 111-120		2
66	Whole exome sequencing of rare aggressive breast cancer histologies. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 21-32	4.4	26

65	Tumor Stroma Manipulation By MSC. <i>Current Drug Targets</i> , 2016 , 17, 1111-26	3	8
64	18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis. <i>Current Radiopharmaceuticals</i> , 2016 , 9, 244-257	1.8	29
63	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , 2016 , 12, 2071-5	3.6	18
62	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016 , 1, e000107	6	8
61	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. <i>Cancer Treatment Reviews</i> , 2016 , 46, 9-19	14.4	60
60	PIK3CA: a Target or a Marker in Breast Cancers. <i>Current Breast Cancer Reports</i> , 2015 , 7, 161-169	0.8	5
59	Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1648-1655	8.8	7
58	Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas. <i>Stem Cells</i> , 2015 , 33, 859-69	5.8	35
57	Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. <i>BMC Cancer</i> , 2015 , 15, 662	4.8	76
56	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2015 , 20, 1001-10	5.7	59
55	Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2881-7	3.1	12
54	Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 511-511	2.2	4
53	Detection of microparticles from human red blood cells by multiparametric flow cytometry. <i>Blood Transfusion</i> , 2015 , 13, 274-80	3.6	29
52	Targeted Therapies for HER2-positive Breast Cancer. <i>Current Clinical Pathology</i> , 2015 , 57-72	0.1	
51	Trastuzumab-containing regimens for metastatic breast cancer. <i>The Cochrane Library</i> , 2014 , CD006242	5.2	97
50	Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1050-7	2.2	40
49	Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. <i>Oncologist</i> , 2014 , 19, 805-137	137	93
48	Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 1041-50	3.5	4

47	Blurring of boundaries in the doctor-patient relationship. <i>Lancet Oncology, The</i> , 2014 , 15, 1423-1424	21.7	10
46	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014 , 40, 847-56	14.4	15
45	Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. <i>Anticancer Research</i> , 2014 , 34, 3657-62	2.3	8
44	Relapsed triple-negative breast cancer: challenges and treatment strategies. <i>Drugs</i> , 2013 , 73, 1257-65	12.1	34
43	The Future of Chemotherapy in the Era of Personalized Medicine. <i>Current Breast Cancer Reports</i> , 2013 , 5, 57-68	0.8	2
42	Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. <i>International Journal of Cancer</i> , 2013 , 132, E58-65	7.5	9
41	Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 395-406	4	57
40	Trastuzumab containing regimens for early breast cancer. <i>The Cochrane Library</i> , 2012 , CD006243	5.2	259
39	The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 157-66	3	6
38	Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1989-95	2.2	284
37	Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. <i>Journal of Clinical Pathology</i> , 2012 , 65, 503-6	3.9	10
36	Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications. <i>Lung Cancer</i> , 2011 , 74, 145-8	5.9	7
35	Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2150-7	3.1	12
34	Bevacizumab treatment for advanced breast cancer. <i>Oncologist</i> , 2011 , 16, 1684-97	5.7	15
33	Timing for starting second-line therapy in recurrent ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 49-55	3.5	8
32	Biomarkers predicting clinical benefit: fact or fiction?. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 63-6	4.8	6
31	Predictive and Prognostic Role of P53 According to Tumor Phenotype in Breast Cancer Patients Treated with Preoperative Chemotherapy: A Single-Institution Analysis. <i>International Journal of Biological Markers</i> , 2010 , 25, 104-111	2.8	7
30	Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 181-8	4.4	189

29	Achievements and unmet needs in the management of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 117, 152-8	4.9	68
28	Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. <i>Oncologist</i> , 2009 , 14, 645-56	5.7	80
27	Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 1549-57	3.5	8
26	The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1456-8	4.6	2
25	Triple-negative breast cancer: current management and future options. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 14-18	1.6	8
24	Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). <i>Clinical Breast Cancer</i> , 2008 , 8, 192-4	3	27
23	Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). <i>Clinical Breast Cancer</i> , 2008 , 8, 453-6	3	43
22	Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). <i>Clinical Breast Cancer</i> , 2008 , 8, 97-100	3	14
21	Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. <i>Oncologist</i> , 2008 , 13, 838-44	5.7	116
20	Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 127-34	4.4	16
19	Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 826-36	6.3	466
18	Progress in the Treatment of Early and Advanced Breast Cancer 2008 , 239-256		
17	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. <i>Clinical Breast Cancer</i> , 2007 , 7, 34-42	3	115
16	Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. <i>Clinical Breast Cancer</i> , 2007 , 7, 841-9	3	12
15	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3399-406	2.2	250
14	Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. <i>Cancer Letters</i> , 2007 , 248, 175-85	9.9	18
13	Controversies of chemotherapy for the treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 11-16	1.6	2
12	Clinical utility of measuring circulating tumor cells in metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2006 , 7, 85-6	3	1

11	Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. <i>Clinical Breast Cancer</i> , 2006 , 7, 326-30	3	18
10	Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1037-44	2.2	453
9	Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4107-15	2.2	295
8	Predictive value of biologic parameters for primary chemotherapy in operable breast cancer. <i>Clinical Breast Cancer</i> , 2005 , 6, 315-24	3	6
7	In Response to Body Letter to the Editor Regarding Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens <i>Oncologist</i> , 2005 , 10, 318-319	5.7	2
6	Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. <i>Oncologist</i> , 2005 , 10, 842-8	5.7	73
5	In Response to Jackson Letter to the Editor Regarding Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens <i>Oncologist</i> , 2005 , 10, 315-316	5.7	1
4	Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. <i>Oncologist</i> , 2004 , 9 Suppl 4, 28-37	5.7	172
3	The curability of breast cancer and the treatment of advanced disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004 , 31 Suppl 1, S149-61	8.8	105
2	Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. <i>Cancer</i> , 2004 , 101, 704-12	6.4	103
1	Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2002 , 3, 346-52		5